Evidence map›Paper›PMID 40713598›Full record

ArticleAIDS research and therapy2025

HIV drug resistance in children and adolescents on NNRTI-based antiretroviral therapy and subsequent virologic response to dolutegravir-based regimens in Ghana.

Adwoa K A Afrane, Vlad Novitsky, Joel Hague, Kwamena Sagoe, Yakubu Alhassan, Joycelyn Assimeng Dame, Charles Martyn-Dickens, Margaret Lartey, Bamenla Goka, Kwasi Torpey and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Adwoa K A AfraneDepartment of Child Health, University of Ghana Medical School and Korle- Bu Teaching Hospital, Accra, Ghana. akaafrane@ug.edu.gh.
Vlad NovitskyDivision of Infectious Diseases, Brown University Alpert Medical School, Providence, Rhode Island, USA.
Joel HagueDivision of Infectious Diseases, Brown University Alpert Medical School, Providence, Rhode Island, USA.
Kwamena SagoeDepartment of Medical Microbiology, University of Ghana Medical School, Accra, Ghana.
Yakubu AlhassanDepartment of Biostatistics, School of Public Health, University of Ghana, Legon, Accra, Ghana.
Joycelyn Assimeng DameDepartment of Child Health, University of Ghana Medical School and Korle- Bu Teaching Hospital, Accra, Ghana.
Charles Martyn-DickensDirectorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Margaret LarteyDepartment of Medicine and Therapeutics, University of Ghana Medical School and Korle-Bu Teaching Hospital, Accra, Ghana.
Bamenla GokaDepartment of Child Health, University of Ghana Medical School and Korle- Bu Teaching Hospital, Accra, Ghana.
Kwasi TorpeyDepartment of Population, Family and Reproductive Health, School of Public Health, University of Ghana, Accra, Ghana.
Rami KantorDivision of Infectious Diseases, Brown University Alpert Medical School, Providence, Rhode Island, USA.
Awewura KwaraDivision of Infectious Diseases and Global Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH · 1998 to 2026
$51.7M
Training Program in Tuberculosis and HIV Research in GhanaD43TW010055 · FIC · UNIVERSITY OF FLORIDA · PI KWARA, AWEWURA JACOB · 2015 to 2019
$1.5M
HIV Drug Resistance, Monitoring and TransmissionK24AI134359 · NIAID · MIRIAM HOSPITAL · PI Rami Kantor · 2018 to 2026
$1.3M
FIC NIH HHS D43 TW010055NIAID NIH HHS K24 AI134359NIAID NIH HHS P30 AI042853NIH grant K24AI134359University of Ghana's Office of Research Innovation and Development URGF/14ECG-0052022-2023
6 · The paper itself

Abstract

HIV drug resistance (HIVDR) was retrospectively characterized among 20 children and adolescents with HIV with virologic failure on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy, and virologic response in those switched to dolutegravir (DTG)-based therapy described. All participants had at least one NNRTI resistance mutation, most commonly K103N (N = 12) and 15 (75%) had nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations, most commonly M184I/V (N = 15). Five (45%) of 11 participants who were switched to DTG-based regimens for a median of 50 months had HIV suppression. Further studies to understand the role of pre-existing HIVDR in the failure of DTG-based regimens are needed.

Indexed as

Anti-HIV AgentsDrug Resistance, ViralHeterocyclic Compounds, 3-RingHIV-1HIV InfectionsHIV Integrase InhibitorsReverse Transcriptase InhibitorsAdolescentChildChild, PreschoolDolutegravirFemaleGhanaHumansMaleMutationAnti-HIV AgentsDolutegravirHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsOxazinesPiperazinesPyridonesReverse Transcriptase InhibitorsAntiretroviral therapyChildren and adolescentsDolutegravirGhanaHIV drug resistanceNNRTIs

Identifiers

PMID40713598
PMCPMC12296613

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.